dxpx general logo white text

Unlock growth opportunities through high-powered networking in Diagnostics, Digital Health, Precision Medicine, and Life Sciences Tools.

Reception: Sunday, January 26, 2025
Partnering Day & 42PLUS1: January 27, 2025

Referred by Kurma Partners?
Save another 20% and attend the DxPx conference.

  • Exclusive Discounts: Sign up for the €499 42PLUS1 Applicant Ticket and apply code kurma-20 at checkout for an additional €100 discount.
  • Meet growth companies, investors, and decision-makers from Diagnostic, Digital Health, Precision Medicine, and Life Science Tool companies by pre-scheduling one-to-one meetings and setting up your personal itinerary.
  • Exhibit your company to industry executives and showcase products at your booth to get the most out of your DxPx attendance.
  • Learn more about the latest industry trends and market insights from our DxPx panelists and speakers to help you identify future opportunities for your business.
  • Compete in our 42PLUS1 pitch competition for your chance to secure up to $2 million in funding. Learn more at 42PLUS1.com.
  • Grow your company by leveraging all that DxPx EU has to offer.

kurma-20

Sign up for the €499 42PLUS1 Applicant Ticket and apply code kurma-20 at checkout for an additional €100 discount.

DxPx Brochure

For more information about the DxPx Conferene, download our brochure.

Investors Participating in Previous DxPx Events

<smallThis is just a sample of some prominent past participants and partners. </small

300_90_investor_dxpx_us_2022_logo cs ventures Greta Holland
300_90_speaker_company_dxpx_eu_2022_logo_thermofisher
DigitalDx-Ventures
300_90_investor_dxpx_us_2022_logo_Becton Dickinson
300_90_investor_company_dxpx_eu_2022_logo_GE_general_electric
investor-logo-oost-nl
300_90_investor_company_dxpx_eu_2022_logo_HSE_AG
300_90_investor_company_dxpx_eu_2022_logo_merck
investor logo kurma partners
investor logo early bird
300_90_investor_company_dxpx_eu_2022_logo
investor logo karista
300_90_investor_company_dxpx_eu_2022_logo_limeston_capital
300_90_investor_company_dxpx_eu_2022_logo_inibio
octopus ventures
investor illumina ventures
300_90_investor_dxpx_us_2022_logo ipf partners
300_90_investor_company_dxpx_eu_2022_logo_aescuvest
300_90_investor_company_dxpx_eu_2022_logo_biotech_inv
300_90_investor_company_dxpx_eu_2022_logo_coelum
300_90_investor_company_dxpx_eu_2022_logo_deeptech_climate_fonds
300_90_investor_company_dxpx_eu_2022_logo_heran
300_90_investor_company_dxpx_eu_2022_logo_ist_cube
300_90_investor_company_dxpx_eu_2022_logo_novalis_biotech_accelerator
300_90_investor_company_dxpx_eu_2022_logo_nrw_venture
300_90_investor_company_dxpx_eu_2022_logo_perspectiv_ventures
300_90_investor_company_dxpx_eu_2022_logo_star_capital
300_90_investor_company_dxpx_eu_2022_logo_stonecaliber_investment
300_90_investor_company_dxpx_eu_2022_logo_szejk_capital
300_90_investor_company_dxpx_eu_2022_logo_TA_ventures
investor logo wellington partners
300_90_investor_company_dxpx_eu_2022_logo_werfen

Date & Location:

January 26 – 27th, 2025

Leonardo Royal Munich
Moosacher Straße 90, 80809 München
Germany

Oliver Dick

Oliver brings 30+ years of experience in the life sciences industry, has worked in pharma, biotechnology and in vitro diagnostics. His areas of expertise fall under Supply Chain Management, Planning, Production, QC, QA, Engineering, Technology Transfer and Process Improvement. Amongst his vast experience, Oliver held functions such as Vice President of Global Manufacturing at QIAGEN, Chief Operating Officer at Miltenyi Biotec or Chief Operating Office of Resolve Biosciences. He demonstrated exceptional leadership and expertise in driving manufacturing excellence on a global scale.

Oliver has a proven ability to streamline processes, optimize production efficiency, and foster a culture of innovation. He was responsible for strategy development, scaling, cost control and quality and was part of multiple M&A projects and transfer of many new products from acquisition or own development. Today Oliver offers his expertise mainly through his own Consultancy Service Company ODICON.

Experience

Christoph Brandenberger is a Managing Director at BGL and a leader in the firm’s Diagnostics, Research Tools & Medical Devices investment banking group. He has more than 20 years of experience in all aspects of mergers and acquisitions, commercialization and partnering agreements, and private placements.

A native of Austria and fluent in German, Christoph’s investment banking experience, coupled with his background in international business, has made him a sought-after advisor in both the domestic and international healthcare markets.

Prior to joining BGL, Christoph served as managing director for Healthios Capital Markets, LLC. Christoph started his career as a financial analyst for Bank of America Securities.

Experience

John Riddle

John Riddle is a Managing Director and member of the BGL Executive Committee. He has more than 30 years of investment banking and capital markets experience, advising clients across a broad spectrum of mergers and acquisitions, capital markets activities, and strategic assignments.

John leads BGL’s advisory activities in the Healthcare & Life Sciences investment banking group, which comprises both corporate investment banking and real estate capital markets capabilities. Together with his team, John maintains an ongoing coverage effort with broad activity across several sectors, including health facilities, physician services, and ancillary providers; diagnostics and research tools; medical device and products; and select healthcare technology verticals, including payor services, data analytics, and clinical automation.

Experience

Dr. Mirko Stange

Born in Bremen, Germany in 1974, Dr. Mirko Stange is a diagnostics and life sciences expert with a proven track record in turning around and commercializing innovations. He possesses extensive executive management experience, having led diagnostics and biotech startups, as well as developing and conducting consulting products. Following the completion of his Ph.D. in Biochemistry and Biophysics at the University of North Carolina at Chapel Hill, Dr. Stange began his career in 2004 at the strategy consultancy McKinsey. Subsequently, he worked with the turnaround-specialized advisory firm Droege & Comp., primarily serving clients from the pharma and chemistry industry in Germany and Switzerland.

In 2008, he founded an independent Life Sciences consultancy in Germany where, to date, he leads and directs a team of international experts. This team identifies and funds SMEs with high potential for national and international leverage. In addition to his over ten years of experience in independent corporate finance and management consulting, Mirko Stange provides interim management services to selected clients. To date, three companies co-founded and managed/advised by Dr. Stange have been successfully exited. Leveraging his scientific background, he is also a named inventor on several granted and pending patents.

Experience

FName LName

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Experience